Hydroxyurea use in young infants with sickle cell disease.
Sarah B SchuchardJennifer R LissickAmanda NickelDavid WatsonKristin L MoquistRae M BlaylarkStephen C NelsonPublished in: Pediatric blood & cancer (2019)
HU is safe and effective in patients 5 to 12 months of age and generated a more robust response compared with initiation in older patients.